Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Legend Biotech Corp. LEGN stock fell in Thursday’s premarket trading after the cell therapy company priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 ...

Webcast/Conference Call Details:Legend Biotech will host its quarterly earnings call and webcast today at 8:00 a.m. ET. To access the webcast, please visit this weblink. A replay of the webcast will ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study No dose-limiting toxicities, serious adverse ...

Capacity to meet demand is a challenge for the entire class of CAR-T treatments. With the drugs now moving into earlier lines of therapy, the supply issue takes on added significance, namely whether ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...